目的 观察去感热口服液联合利巴韦林治疗急性上呼吸道感染的临床疗效。方法 选取宣汉县人民医院2015年1月-2015年12月收治的急性上呼吸道感染患者106例，随机分为对照组和治疗组，每组各53例。对照组静脉滴注利巴韦林注射液，0.5 g加入到生理盐水250 mL，1次/d；治疗组在对照组的基础上口服去感热口服液，10 mL/次，3次/d。两组均连续治疗7 d。观察两组患者临床疗效、临床症状体征改善情况，对比两组患者治疗前后白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）指标水平。结果 治疗后，对照组的总有效率为73.58%，显著低于治疗组的92.45%，两组总有效率比较差异有统计学意义（P<0.05）。治疗后，治疗组退热时间、咽痛消失时间、止咳时间及咽部充血消失时间均明显短于对照组，两组比较差异具有统计学意义（P<0.05）。两组患者IL-6和TNF-α指标水平均显著降低，同组差异比较具有统计学意义（P<0.05）；且治疗组两个指标改善情况优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 去感热口服液联合利巴韦林治疗急性上呼吸道感染疗效确切，显著改善症状体征和炎性指标，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of Quganre Oral Liquid combined with ribavirin in treatment of acute upper respiratory tract infection. Methods Patients (106 cases) with acute upper respiratory tract infection in Xuanhan County People's Hospital from January 2015 to December 2015 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were iv administered with Ribavirin Injection, 0.5 g added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Quganre Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy, clinical symptoms and signs were evaluated, and IL-6 and TNF-α level in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.58%, which was significantly lower than 92.45% in the treatment group, and there was difference between two groups (P<0.05). After treatment, pyretolysis time, disappearing time of pharyngalgia, cough, and pharyngeal hyperemia in treatment group were significantly shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, IL-6 and TNF-α levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the two indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Quganre Oral Liquid combined with ribavirin has clinical effect in treatment of acute upper respiratory tract infection, can significantly improve symptoms and signs,and inflammatory indexes, which has a certain clinical application value.